Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

    ArborGen Holdings

    MCap

    NZD77m

    Last close

    NZD0.15

    ▲ 0.01 (7.14%)

    ICL Group

    MCap

    USD5,729m

    Last close

    USD4.44

    ▲ 0.29 (6.99%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sareum Holdings (AIM: SAR)

Last close As at 04/11/2024

GBP0.26

▲ 0.50 (1.96%)

Market capitalisation

GBP33m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Latest Insights

View More

Healthcare | Flash note

Sareum Holdings — New funding extends runway to Phase II

Healthcare | Flash note

Sareum Holdings — SDC-1801 records positive Phase Ia data

Healthcare | Update

Sareum Holdings — A decisive period ahead for SDC-1801

Healthcare | Flash note

Sareum Holdings — Positive clinical step forward in SDC-1801
Sareum Holdings_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

Balance Sheet

Forecast net cash (£m)

0.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (5.5) (13.3) (58.4)
Relative (4.2) (13.2) (62.5)
52 week high/low 67.5p/10.2p

Financials

Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial for its lead asset SDC-1801, a next-generation TYK2/JAK1 kinase inhibitor. Management expects the combined funds to support preparatory activities, including longer-term toxicology studies, as the candidate advances towards Phase II trials in psoriasis patients. As a reminder, the company had presented encouraging Phase I top-line data for SDC-1801 in July 2024, and has now reported further positive insights from the unblinded data (detailed below). Based on the Phase I readout, and supported further by additional data from the planned toxicology studies, we expect Sareum to seek partnering opportunities before proceeding to Phase II, likely in 2025.

Research

Flash note

Healthcare

Sareum Holdings — SDC-1801 records positive Phase Ia data

Update

Healthcare

Sareum Holdings — A decisive period ahead for SDC-1801

Healthcare

Flash note

Sareum Holdings — New funding extends runway to Phase II
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free